DOI: 10.1111/J.1365-2125.2010.03879.X
关键词: Platelet activation 、 Glycoprotein IIb/IIIa 、 Clinical trial 、 Platelet aggregation inhibitor 、 Heparin 、 Pharmacology 、 Medicine 、 Conventional PCI 、 Platelet 、 Platelet Glycoprotein GPIIb-IIIa Complex
摘要: Glycoprotein (GP) IIb-IIIa antagonists inhibit the aggregation of activated platelets. Three agents are approved for clinical use. In this review, characteristics each agent, their pharmacodynamic profile, results in pivotal trials and associated implications discussed. GP have greatest benefit when used as adjunctive therapy during percutaneous coronary intervention (PCI) patient has intra-coronary thrombosis. These appear to provide combination with heparin. The niche parenteral is evolving. rapid onset offset plus dosing designed extensively platelet differentiates them from oral agents. contemporary appears include patients transition, such individuals requiring emergent PCI before fully active unstable transport centres, particularly likely intracoronary thrombus. Subsequent studies should evaluate optimal duration antagonists.